Posts Tagged Real-world evidence

Closing Gaps in Real-World Evidence through Data Linkage

Interview with Dr. Kevin Haynes, Principal Scientist, HealthCore-NERI.

Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Kevin Haynes, Principal Scientist at HealthCore-NERI, to discuss closing gaps in real-world evidence through data linkage. The mission of HealthCore-NERI is to provide clarity that empowers decision makers to act with precision to improve quality, safety, and affordability in health care. HealthCore-NERI works with life science companies, payers and providers, and government and academic organizations to provide real-world evidence in support of a wide variety of health care decisions.

Dr. Peeples: Why is fragmentation in health care so important to health care researchers, and specifically real-world evidence?

Dr. Haynes: The fact that patients can seek care across health care systems, may move across geographies over time, and may change health plans fragments the patient journey within the health system. This fragmentation within the US health care system creates fragmentation of health care data and this data fragmentation inhibits our ability to generate high-quality evidence. In my opinion, the biggest gap to close is a gap in data. When we close the data gap, then we can begin to close the gaps in evidence. The same gaps in data that prevent us from generating high-quality evidence also create gaps in care. These gaps are closing as Health Information Exchanges, all-payer claims databases, and data integration with prescription dispensing records feed back into electronic medical record systems. As these data gaps close, our ability to generate high-quality evidence will improve. One area of data fragmentation is in the patient journey across health care systems creating a long-term fragmentation. As people traverse a lifetime of follow up periods, we traverse periods of our lives moving from childhood to college and early careers. This creates a fluid space of data moving across health plans as jobs, spouse, and life circumstances change our insurance coverage and access to health care systems. Today we need to be developing the infrastructure to be able to address these research issues moving forward. This is a long-term game as fragmentation of health care delivery currently has an impact on our ability to conduct observational comparative effectiveness research over a lifetime. Another area of fragmentation is cross-sectional data fragmentation which occurs as we seek care across health systems. For example in cancer we invariably fragment care as we instruct patients to seek a second opinion. As such tests and work up may be contained within one health system’s electronic records and treatment and longitudinal follow-up may be contained in a second health system’s electronic record.

Dr. Peeples: What are some of the biggest issues among stakeholders (providers, payers, patients, researchers, policy makers)?

Dr. Haynes: The biggest issue for stakeholders is data privacy and the governance required to manage the use of data for various purposes. There is clear governance with regards to HIPPA and other privacy considerations that govern the research aspects of data. Often the use of observational data at the institutional level notes loss of confidentiality as the only risk to the patient, and ensures that all data will be stored on secure servers with limited access. However, we are in an era now where we need to link to other data sources to close gaps in data fragmentation. This creates a need to utilize protected health information or personal identifiable information which may increase the risk to study participants in observational research. Therefore, we need to implement the technology to improve data privacy.

Dr. Peeples: With the fragmentation of health care across health systems, what do you see as the opportunities to overcome these data fragmentation challenges to enhance real-world evidence?

Dr. Haynes: There is tremendous opportunity as there is a lot going on in the data linkage space as people develop relationships with patients. For example, researchers involved in PCORnet’s Patient or People Powered Research Networks (PPRNs), the NIH’s All of Us, and other commercial ventures – are developing relationships with patients. They are able to get and seek, not only the consent, but also the authorization to link data across resources to develop the evidence that is needed. When researchers have access to patients, it is important to obtain sufficient patient authorization to conduct these linkage activities. Other opportunities exist in the space of protecting patient privacy in observational research, such as creating privacy protection record linkage.

Dr. Peeples: How do we do the data linkage? Are there specific use cases that have been successful?   

Dr. Haynes: One must either obtain patient consent through a relationship with the patient or utilize privacy-preserving record linkage strategies. For example, patients participating in PCORnet’s ADAPTABLE study, which seeks to identify the most appropriate dose of aspirin for secondary prevention of cardiovascular morbidity – have consented to participate. The study is therefore able to outreach and obtain authorization from participants to allow their health plan to share limited longitudinal information to help address one of the data gaps with regards to this study. Among PCORnet’s demonstration studies is a large obesity observational study looking at the effect of pediatric antibiotic exposure on the microbiome and the effect of weight gain at 5 and 10 years. This study is involving hundreds of thousands of patients. Considering the impossibility of obtaining the consent of or relationship with all patients, researchers are employing privacy-preserving record linkage to facilitate linkage of health plan pharmacy claims with clinical data.

Dr. Peeples: Patient privacy is of vital importance in the conduct of data linkage. How do you conduct the research and ensure patients their privacy is not being breached? What changes have occurred over time? What do you do that is a higher bar than is necessary, if anything?

Dr. Haynes: We as researchers need to develop the trust with our patients, especially patients who are recruited and enrolled in clinical trials where we have a relationship with the patient, to seek the necessary authorizations to do these linkages. We must also ensure that these linkages are used only for that intended purpose. As such, there is a need for governance around data use. When we have a relationship with the patient, we have an obligation to educate and inform patients in things like the ADAPTABLE study, the All of Us study, potential patient registries, and others, to inform patients of the importance of the linkage and that the linkage activities will be governed in such a way as to protect patient privacy. We also have a societal obligation to ensure that any linkage activities utilizing privacy-preserving record linkage modalities protect patients and their privacy.

Dr. Peeples: Expanding on the concept of data linkage, are there disease or therapeutic areas that are particularly challenging? Or areas where this data linkage has shown success?  

Dr. Haynes: There are tremendous opportunities and areas that are particularly challenging in this space of linkage. These challenges focus on both linking longitudinally and on linking over defined time periods to get deep clinical data. One example is in the opioids space where many states have prescription drug monitoring programs (PDMP). These programs are designed to capture all of the opioid prescriptions such that providers can access this resource and ensure that they have a complete picture of exposure to opioids across health systems. Pharmacists have an opportunity to assess this system to evaluate opioid utilizations beyond their pharmacy. These systems are designed to close a gap in care. However, one challenge is that these systems are not able to be utilized by health plans to potentially close gaps in evidence. The high-quality exposure information from state PDMP and the high quality outcome data from health plans would provide an opportunity to address evidence in the opioid epidemic.

Dr. Peeples: What are the ultimate rewards of linked data resources for RWE?  

Dr. Haynes: The most important thing from an epidemiologic standpoint to linked data is to reduce what we call information bias. There are several forms of information bias, including misclassification. Therefore, capturing outcomes or exposures of interest and knowing that you have complete capture is vital to the conduct of real-world data analysis.

Dr. Kevin Haynes, PharmD, MSCE, is a Principal Scientist at HealthCore-NERI. He is the Principal Investigator on two Patient Centered Outcomes Research Institute (PCORI) awards and the site Principal Investigator for HealthCore within the FDA Sentinel Initiative as well as a Data Core Co-Lead on Sentinel. At HealthCore-NERI, Dr. Haynes is currently responsible for developing responses to proposals and providing clinical pharmacoepidemiology expertise to various projects. Dr. Haynes has more than 14 years of experience in clinical pharmacy, clinical research, epidemiology, pharmacoepidemiology, surveillance, medical informatics, and project management. In addition, he has extensive experience collaborating with the Food and Drug Administration as well as multiple investigators on pharmacoepidemiology projects.

, , ,

No Comments

Storytelling, Giving Back, and Legacy: How AESARA is Doing it Differently

A market access agency.

A few months ago, I was sipping my morning coffee and perusing the health economics and outcomes research (HEOR) news feed as I do twice daily for HealthEconomics.Com. I stumbled across a blurb about a market access firm devoting time, talent and treasure to disaster relief from Hurricane Irma and Maria. The company was AESARA. One of my long-time colleagues, Dr. Lynn Okamoto, was in a leadership position there; being intrigued, I delved a bit deeper.

You see, I’m always keen to showcase the extraordinary individuals who make up the HEOR, Market Access (MA) and real-world evidence (RWE) field, and in my own small way attempt to debunk the myth that we are just geeky scientists. Many of you may remember a series that HealthEconomics.Com did a few years ago called HE-Artists: Health Economists and their Artistic Passions. This series revealed the breadth of impact made by our HEOR community, and showcased many phenomenal, multi-faceted, talented individuals who make their corner of the world a better place, while also doing extraordinary work in their careers.

As I read more about AESARA, I found a group of individuals who were indeed following their passion as a digital-forward market access agency. But also, I found a leader who was intent on making change in both HEOR and in needy communities around the globe. Meet Sissi Pham, Pharm D, Chief Executive Officer and Lynn Okamoto, PharmD, Chief Business and Technology Officer of AESARA. Sissi prefers not to showcase her or the staff’s pictures on their website, but rather, to use metaphors and symbolism to highlight their individual and corporate mission.

Sissi’s symbol is the Delta glyph and Lynn’s symbol is Theta. Each staff member has a symbol, and the personal meaning of these symbols is described here. Below is my interview with Dr. Sissi Pham, with additional commentary by Dr. Lynn Okamoto.

[PP] What life experiences or events influenced you as a person and female executive in the HEOR field?

[SP] What influences me as a person, the work I do, and the mission of AESARA are all driven by being an immigrant to this country. I am Vietnamese by origin and I arrived in America with my parents and two other siblings at the end of the Vietnam War in 1975. My parents built a life for their children filled with many opportunities, even though they started here with absolutely nothing. It was very impactful to watch how my parents made change happen. My parents had high expectations from all of us to make a difference and “do good”. 

Another influence was a combination of my age and a significant event with my loved one. I was turning 50 years old and simultaneously, my father was passing away with two types of cancer. These events coalesced with a personal inventory of my purpose, and questions of whether I was doing all I could to make my father proud of the sacrifice he had made for me. 

Thirdly, I wondered about my legacy, my meaning in life. I do not have children but have been fortunate enough to earn a good living.  I saw examples of successful business leaders implementing a culture of philanthropy and social giving. I was inspired by this and made the decision that my next business venture would include this approach.

 [PP] Describe what a digital-forward market access agency is and how AESARA is doing things differently?

[SP] I have always enjoyed packaging and translating HEOR science and information to be used by the sales force and medical science or health outcomes liaisons with their customers. As a discipline, we are very challenged with how to communicate efficiently and effectively to the patients, providers and payers.  There is so much technology available – beyond Excel™ and PowerPoint™ – that we are not using in the health outcomes and market access space.

So, I started AESARA in April 2016 as a health outcomes market access agency similar to the brand or commercial agency that supports the product marketing in pharma. However, we don’t just do the creative work, we are also subject matter strategists; we have the subject matter expertise to turn the data in digestible content that can be used for decision-making and patient access.

[PP] Specifically, what are you doing differently with communication tools?

[SP] If you think about Ogilvy, they deliver glossy brochures, slide decks, and other very visual content that includes simple and actionable marketing language. In the commercial sector, agencies have learned how to distill complex clinical trial information into material that communicates the message for a brand to providers. At AESARA, we are trying to do something similar with HEOR and budget impact model data, or any of the evidence necessary for value-based decisions.

I am a big follower of Nancy Duarte and the Duarte Method. We use this approach to package evidence for our clients. In addition, our Creative team specializes in graphics that are grounded in the language we (HEOR) speak.

Truthfully, the digital forward component is something that pharma has been slower to adopt. We are moving this up in adoption curve and are using interactive pieces to support the communication of all forms of evidence: dossier, infographics, and other tools with the intent of disrupting the value communication space.

[PP] Lynn Okamoto’s focus is technology. Tell us more about what you are trying to accomplish.

[LO] Our HEOR, RWE and Market Access field is document-heavy, often relying upon old systems for collaborating and sharing. We are creating systems to be used internally by clients that allow them to be more productive, more efficient, and more quickly identify where evidence needs to be updated, then share final documents globally in real-time. This allows people to get the information they need for better decision-making. We are focusing on streamlining and strengthening these linkages across people and documents.

[PP] Let’s circle back to what intrigued me initially about AESARA – your Foundation. What is the mission and what have you accomplished so far?

[SP] Our Foundation is in its early days, being just 3 years old. I wanted to build a company that could sustain a Foundation over time. It’s a commitment we’ve made as a company. We haven’t clearly defined exactly what we support. It’s not targeted yet. We aren’t quite there yet. But we do know – and all of our employees support this – that we have an interest in giving back.

As I continue to formulate the Foundation purpose, I keep coming back to our strengths. We have world-class talent on the business side, including skilled health economists, as well as operations, technology, and finance capabilities. How can we leverage this, pro bono, to improve healthcare?

We began to do this in Puerto Rico after Hurricane Maria.  We focused our efforts on Loíza, Puerto Rico with 25 volunteers consisting of AESARA employees and family members.  In addition to hands-on disaster assistance efforts like painting and tiling homes and roof installation, we used our in-house consulting skills to help problem-solve for this community to help prepare for the next disaster. We helped develop a plan to upgrade their current urgent care center, as well as figure out ways to establish emergency shelters and use these effectively in between emergency use.  Moreover, we contribute to a collective funding across multiple agencies to maximize the disaster relief efforts.

[LO] Everyone we hire at AESARA values the Foundation and its focus. Today, many of employees represent a generation that wants to find a way to give back.  Joining a company who values that is very important to them, and these are the kind of individuals we want to hire.

[PP] Let’s close with a look into the future. What do you wish was different in our HEOR field in 10 years?

[SP] I hope the HEOR & Market Access data we generate is on par with the clinical evidence, that the customers understand it, and use it to make decisions.

If you’d like to know more about AESARA, visit

If you’d like to have your organization or leadership featured in Profiles from the HEOR C-Suite, contact Dr. Patti Peeples, CEO of HealthEconomics.Com

, , , , ,

No Comments